This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Mallinckrodt (MNK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again
by Zacks Equity Research
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com featured highlights include: Mallinckrodt, Sony and Public Storage
by Zacks Equity Research
Zacks.com featured highlights include: Mallinckrodt, Sony and Public Storage
Top Ranked Growth Stocks to Buy for October 22nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, October 22nd
J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos
by Zacks Equity Research
J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.
Top 3 ROE Stocks to Profit as Earnings Season Heats Up
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Will Mallinckrodt Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Mallinckrodt.
Is the Options Market Predicting a Spike in Mallinckrodt (MNK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
J&J Settles Ahead of Multi-District Opioid Trial, Stock Up
by Zacks Equity Research
J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.
Mallinckrodt Up on Settlement Agreement With Ohio Counties
by Zacks Equity Research
Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.
Mallinckrodt's StrataGraft Tissue Phase III Data Positive
by Zacks Equity Research
Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.
Implied Volatility Surging for Mallinckrodt (MNK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up
by Zacks Equity Research
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties
by Zacks Equity Research
Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.
Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation
by Zacks Equity Research
Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.
Mallinckrodt (MNK) Down 54.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Opioid Litigation Take its Toll on Pharma Companies?
by Indrajit Bandyopadhyay
Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.
Case-Shiller Index Nudges Up
by Zacks Equity Research
Case-Shiller Index Nudges Up
J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read
by Mark Vickery
Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.
Mallinckrodt (MNK) Stock Down 70.8% YTD on Numerous Lawsuits
by Zacks Equity Research
Mallinckrodt (MNK) crashes 70.8% in the year so far due to various lawsuits and litigations.
Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
Is Mallinckrodt (MNK) a Profitable Pick for Value Investors?
by Zacks Equity Research
Mallinckrodt (MNK) stock may be a good choice for value-oriented investors right now from multiple angles.
Mallinckrodt Enrolls First Patient in Liver Disease Study
by Zacks Equity Research
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold
by Zacks Equity Research
Mallinckrodt (MNK) beats on earnings in Q2 but marginally misses on revenues. The company suspends plan to spin-off the generic business for now.
Company News For Aug 6, 2019
by Zacks Equity Research
Companies in the news are: AGN, ENR, EPC and MNK